From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

How Much Will the First Responder Anthrax Preparedness Act Cost?

by Global Biodefense Staff
January 20, 2016
Anthrax Preparedness

The Congressional Budget Office (CBO) this week released their cost estimate of the S. 1915 First Responder Anthrax Preparedness Act.

Under the bill, anthrax vaccines from the U.S. Strategic National Stockpile would be provided to first responders who volunteer to receive them, and the Department of Homeland Security (DHS) would establish a tracking system for the vaccine and would provide educational outreach for the program.

Vaccines nearing the end of their labeled dates would be prioritized for utilization under the Act.

The bill would direct DHS, in coordination with the U.S. Department of Health and Human Services, to establish a pilot program in at least two states to begin providing the vaccine.

Based on information provided by DHS and HHS, CBO estimates that implementing S. 1915 would cost about $4 million over the 2016-2020 period, assuming appropriation of the necessary amounts.

On June 24, 2015, CBO transmitted a cost estimate for house bill H.R. 1300, the First Responder Anthrax Preparedness Act, as ordered reported by the House Committee on Homeland Security.

Sen. Ayotte, Kelly [R-NH] introduced S. 1915 on August 3, 2015. CBO’s estimate of the budgetary effects of implementing both pieces of legislation is the same.

From Our Partners
Tags: AnthraxBioterrorismMobile ResponseVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC